A Novel Somatic Mutation in the RET Proto‐oncogene in Familial Medullary Thyroid Carcinoma with a Germline Codon 768 Mutation

In individuals who carry gcrmline mutations in tumor suppressor genes predisposing them to inherited cancer syndromes, occurrence of somatic mutations in the same genes contributes to tumorigenesis. Germline mutations in the RET proto‐oncogene predispose individuals to multiple endocrine neoplasia (MEN) type 2 syndromes. Since these mutations are oncogenic by themselves, somatic mutations in the same gene had been thought unnecessary. Recently, a somatic mutation at codon 918 of RET was reported in medullary thyroid carcinoma (MTC) and C‐cell hyperplasia in patients with MEN 2A or familial MTC (FMTC), suggesting its possible contribution to tumorigenesis. We describe here a novel somatic mutation at codon 919 in a patient with FMTC carrying a gcrmline mutation at codon 768 that may also be related to tumor progression.

[1]  B. Ponder,et al.  Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma. , 1996, Cancer research.

[2]  B. Ponder,et al.  Genotype‐phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium , 1995, Journal of internal medicine.

[3]  M. Schlumberger,et al.  RET mutations in exons 13 and 14 of FMTC patients. , 1995, Oncogene.

[4]  N. Asai,et al.  Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations , 1995, Molecular and cellular biology.

[5]  B. Ponder,et al.  A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. , 1995, Oncogene.

[6]  al. et,et al.  Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B , 1995, Science.

[7]  R. Hofstra,et al.  DNA polymorphisms and conditions for SSCP analysis of the 20 exons of the ret proto-oncogene. , 1994, Oncogene.

[8]  P. Goodfellow,et al.  Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[9]  R. Hofstra,et al.  A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma , 1994, Nature.

[10]  D. Clayton,et al.  Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC , 1994, Nature Genetics.

[11]  A. Knudson,et al.  Antioncogenes and human cancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[12]  B. Ponder,et al.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A , 1993, Nature.

[13]  T. Sekiya,et al.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. , 1989, Genomics.

[14]  S. Baylin,et al.  Familial medullary thyroid carcinoma without associated endocrinopathies: A distinct clinical entity , 1986, The British journal of surgery.

[15]  S. Wells,et al.  Provocative Agents and the Diagnosis of Medullary Carcinoma of the Thyroid Gland , 1978, Annals of surgery.